Business
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
NEW YORK, June 30, 2025--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced positive 1-year event free survival (EFS), overall survival and safety clinical trial data updates from the 40 patient treatment arm of its Phase 2b clinical trial of immunotherapy candidate OST-HER2 in the prevention or delay of recurrence in fully resected, lung metastatic osteosarcoma. In data presen
About this update from Os Therapies Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/67ad4fd5d8417d76c9b41edb1907e54f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/02vnhD96ywwhHACqlvMQKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/67ad4fd5d8417d76c9b41edb1907e54f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/j6L0TklHLV1HsJ0y3QOvQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/67ad4fd5d8417d76c9b41edb1907e54f","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control (20%)","length":206,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company also provides regulatory update on comparator for OST-HER2 Phase 2b Trial in the Prevention or Delay of Recurrence in Fully Resected, Lung Metastatic Osteosarcoma","length":170,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Responses to recent FDA Type D Meeting follow-up questions submitted by OS Therapies","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":460,"olType":false},{"type":"text","content":"NEW YORK, June 30, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced positive 1-year event free survival (EFS), overall survival and safety clinical trial data updates from the 40 patient treatment arm of its Phase 2b clinical trial of immunotherapy candidate OST-HER2 in the prevention or delay of recurrence in fully resected, lung metastatic osteosarcoma. In data presented by Principal Investigator Dr. Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah on Saturday June 28, 2025 the following data updates were released:","length":720,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"35% (14 out of 40) of OST-HER2-tr...